Surging Prevalence Of Cardiovascular Diseases Propels Growth In The Angina Pectoris Drug Market: Powering Innovation and Expansion in the Angina Pectoris Drugs Market by 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Angina Pectoris Drugs Market Through 2025?
The market for angina pectoris medications has seen robust expansion in the past few years. An increase from $12.32 billion in 2024 to $12.94 billion in 2025 is projected, marking a compound annual growth rate (CAGR) of 5.1%. This growth during the historic period can be credited to factors such as the widespread incidence of cardiovascular diseases, the aging demographic, lifestyle influences, and the escalating rates of hypertension and diabetes.

What's the Projected Size of the Global Angina Pectoris Drugs Market by 2029?
The market for angina pectoris drugs is anticipated to experience robust growth in the upcoming years, expanding to "$16.55 billion by 2029 with a compound annual growth rate (CAGR) of 6.3%. Factors contributing to this growth in the estimated period are an increase in global obesity rates, progress in precision medicine, an emphasis on preventive cardiology, patient education programs, and studies on new therapeutic targets. Major future trends include the use of telemedicine for remote monitoring, real-world evidence and outcome research, patient-focused medication education, strategic partnerships for market penetration, advancements in regulations, and fast-tracked approvals.

View the full report here:
https://www.thebusinessresearchcompany.com/report/angina-pectoris-drugs-global-market-report

Top Growth Drivers in the Angina Pectoris Drugs Industry: What's Accelerating the Market?
The rise in cardiovascular diseases is anticipated to drive the growth of the angina pectoris drug market. Cardiovascular diseases, including various disorders that affect the heart and blood vessels such as coronary artery disease, high blood pressure, heart failure, and stroke. The rise in such diseases can be linked to many factors such as an aging demographic, unhealthy lifestyles, and the obesity crisis. Drugs for angina pectoris like nitrates, beta-blockers, and calcium channel blockers effectively alleviate chest pain and discomfort from inadequate blood supply to the heart, thereby improving the overall quality of life of patients. As an illustration, in September 2024, data from the British Heart Foundation, a cardiovascular research charity based in the UK, showed that about 7.6 million people in the UK suffer from heart and circulatory diseases. This includes around 4 million males and 3.6 million females. These diseases account for approximately 27% of all fatalities in the UK, resulting in over 170,000 deaths yearly, or roughly 480 deaths each day - this equates to one death every three minutes. This rising prevalence of cardiovascular diseases is thus propelling the expansion of the angina pectoris drug market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10797&type=smp

What Trends Will Shape the Angina Pectoris Drugs Market Through 2029 and Beyond?
A prominent trend emerging in the angina pectoris drug market is product innovation. Major players in this sphere are leveraging novel technologies to reinforce their industry positions. For example, Hikma Pharmaceuticals PLC, a UK-based pharma firm, unveiled Labetalol Hydrochloride Injection, USP, in a prefilled syringe in March 2023. This product received endorsement from the United States Food and Drug Administration. In medical facilities, this 10 mg/2 mL PFS is being utilized for the treatment of severe hypertension and the reduction of blood pressure.

What Are the Main Segments in the Angina Pectoris Drugs Market?
The angina pectoris drugs market covered in this report is segmented -

1) By Drugs: Nitrates, Antiplatelet Agents, Beta-adrenergic Blocking Agents, Calcium Channel Blockers, Anti-ischemic Agents, Statins, Antihypertensive Agents, Other Drugs
2) By Indication: Stable Angina, Unstable Angina, Prinzmetal's Angina
3) By Route of Administration: Oral, Parenteral, Transdermal, Other Route Of Administrations
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:
1) By Nitrates: Short-Acting Nitrates, Long-Acting Nitrates
2) By Antiplatelet Agents: Aspirin, Clopidogrel
3) By Beta-Adrenergic Blocking Agents: Non-Selective Beta Blockers, Selective Beta Blockers
4) By Calcium Channel Blockers: Dihydropyridine Calcium Channel Blockers, Non-dihydropyridine Calcium Channel Blockers
5) By Anti-Ischemic Agents: Ranolazine, Ivabradine
6) By Statins: Atorvastatin, Rosuvastatin

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=10797&type=smp

Which Top Companies are Driving Growth in the Angina Pectoris Drugs Market?
Major companies operating in the angina pectoris drugs market include Astellas Pharma Inc., Bayer AG, Novartis AG, AstraZeneca PLC, Bausch Health Companies Inc., Merck & Co Inc., Eli Lilly and Company, Pfizer Inc., Abbott Laboratories, Sun Pharmaceutical Industries Limited, Sanofi SA, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Johnson & Johnson, AERIE PHARMACEUTICALS INC., AbbVie Inc., Amgen Inc., Gilead Sciences Inc., GlaxoSmithKline plc, H. Lundbeck A/S, Ipsen S.A., Lupin Pharmaceuticals Inc., Merck KGaA, Otsuka Pharmaceutical Co. Ltd., Regeneron Pharmaceuticals Inc., Servier Laboratories, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., UCB S.A.

Which Regions Will Dominate the Angina Pectoris Drugs Market Through 2029?
North America was the largest region in the angina pectoris drugs market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the angina pectoris drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10797

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Learn More About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.